Stem Cell Stocks: Pluristem Therapeutics And Lung Disease

Today's Pluristem announcement included the following statement concerning a preclinical investigation of PLX cells in treating -- in the words of Thomson Reuters, 'Pulmonary fibrosis; where a person`s lungs become so scarred that breathing is impossible.'  The investigation was conducted by Dr. Bernard Thebaud of the University of Alberta.

"In this animal model, mice treated with PLX cells showed approximately a 70% statistically significant decrease in collagen protein deposition in the lungs, in comparison to the control treated group. This significant reduction in collagen deposition, attributed to the PLX treatment, emphasizes the potential of PLX to treat the devastating pathogenic endpoint of pulmonary fibrosis. The effect of PLX on the collagen deposition also resulted in an improved lung capacity as represented by increased weight gain and improved oxygen saturation in the treated mice as compared to the control group."

Your guess is as good as ours as to what that first sentence means. Whatever it actually means, the video below from the same researcher at the University of Alberta suggests other types of cells do pretty much the